- Home
- CANF vs SYNX Comparison
CANF vs SYNX Comparison
Compare CANF & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SYNX
- Stock Information
- Founded
- CANF 1994
- SYNX 2005
- Country
- CANF Israel
- SYNX Israel
- Employees
- CANF N/A
- SYNX N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- CANF Health Care
- SYNX
- Exchange
- CANF Nasdaq
- SYNX Nasdaq
- Market Cap
- CANF 9.6M
- SYNX 11.3M
- IPO Year
- CANF N/A
- SYNX 2024
- Fundamental
- Price
- CANF $0.65
- SYNX $1.58
- Analyst Decision
- CANF Strong Buy
- SYNX
- Analyst Count
- CANF 2
- SYNX 0
- Target Price
- CANF $14.50
- SYNX N/A
- AVG Volume (30 Days)
- CANF 171.1K
- SYNX 145.2K
- Earning Date
- CANF 08-26-2025
- SYNX 10-02-2025
- Dividend Yield
- CANF N/A
- SYNX N/A
- EPS Growth
- CANF N/A
- SYNX N/A
- EPS
- CANF N/A
- SYNX N/A
- Revenue
- CANF $560,000.00
- SYNX $9,094,000.00
- Revenue This Year
- CANF $461.72
- SYNX $32.35
- Revenue Next Year
- CANF N/A
- SYNX N/A
- P/E Ratio
- CANF N/A
- SYNX N/A
- Revenue Growth
- CANF N/A
- SYNX 19.14
- 52 Week Low
- CANF $0.63
- SYNX $1.41
- 52 Week High
- CANF $3.12
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- SYNX 45.13
- Support Level
- CANF $0.64
- SYNX $1.54
- Resistance Level
- CANF $0.68
- SYNX $1.76
- Average True Range (ATR)
- CANF 0.02
- SYNX 0.17
- MACD
- CANF 0.01
- SYNX 0.00
- Stochastic Oscillator
- CANF 41.25
- SYNX 22.97
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.